Historical Valuation
Prime Medicine Inc (PRME) is now in the Fair zone, suggesting that its current forward PS ratio of 30.40 is considered Fairly compared with the five-year average of -4.89. The fair price of Prime Medicine Inc (PRME) is between 1.78 to 4.10 according to relative valuation methord.
Relative Value
Fair Zone
1.78-4.10
Current Price：3.94
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Prime Medicine Inc (PRME) has a current Price-to-Book (P/B) ratio of 3.86. Compared to its 3-year average P/B ratio of 3.99 , the current P/B ratio is approximately -3.23% higher. Relative to its 5-year average P/B ratio of 3.62, the current P/B ratio is about 6.46% higher. Prime Medicine Inc (PRME) has a Forward Free Cash Flow (FCF) yield of approximately -18.42%. Compared to its 3-year average FCF yield of -28.38%, the current FCF yield is approximately -35.12% lower. Relative to its 5-year average FCF yield of -27.00% , the current FCF yield is about -31.78% lower.
P/B
Median3y
3.99
Median5y
3.62
FCF Yield
Median3y
-28.38
Median5y
-27.00
Competitors Valuation Multiple
AI Analysis for PRME
The average P/S ratio for PRME competitors is 15.80, providing a benchmark for relative valuation. Prime Medicine Inc Corp (PRME.O) exhibits a P/S ratio of 30.40, which is 92.44% above the industry average. Given its robust revenue growth of 486.12%, this premium appears sustainable.
Performance Decomposition
AI Analysis for PRME
1Y
3Y
5Y
Market capitalization of PRME increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PRME in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PRME currently overvalued or undervalued?
Prime Medicine Inc (PRME) is now in the Fair zone, suggesting that its current forward PS ratio of 30.40 is considered Fairly compared with the five-year average of -4.89. The fair price of Prime Medicine Inc (PRME) is between 1.78 to 4.10 according to relative valuation methord.
What is Prime Medicine Inc (PRME) fair value?
PRME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Prime Medicine Inc (PRME) is between 1.78 to 4.10 according to relative valuation methord.
How does PRME's valuation metrics compare to the industry average?
The average P/S ratio for PRME's competitors is 15.80, providing a benchmark for relative valuation. Prime Medicine Inc Corp (PRME) exhibits a P/S ratio of 30.40, which is 92.44% above the industry average. Given its robust revenue growth of 486.12%, this premium appears sustainable.
What is the current P/B ratio for Prime Medicine Inc (PRME) as of Jan 10 2026?
As of Jan 10 2026, Prime Medicine Inc (PRME) has a P/B ratio of 3.86. This indicates that the market values PRME at 3.86 times its book value.
What is the current FCF Yield for Prime Medicine Inc (PRME) as of Jan 10 2026?
As of Jan 10 2026, Prime Medicine Inc (PRME) has a FCF Yield of -18.42%. This means that for every dollar of Prime Medicine Inc’s market capitalization, the company generates -18.42 cents in free cash flow.
What is the current Forward P/E ratio for Prime Medicine Inc (PRME) as of Jan 10 2026?
As of Jan 10 2026, Prime Medicine Inc (PRME) has a Forward P/E ratio of -3.63. This means the market is willing to pay $-3.63 for every dollar of Prime Medicine Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Prime Medicine Inc (PRME) as of Jan 10 2026?
As of Jan 10 2026, Prime Medicine Inc (PRME) has a Forward P/S ratio of 30.40. This means the market is valuing PRME at $30.40 for every dollar of expected revenue over the next 12 months.